• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vivani Medical Inc.

    4/29/26 4:31:07 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    DEFA14A 1 MainDocument.htm DEFA 14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    VIVANI MEDICAL, INC.

    (Name of Registrant as Specified In Its Charter)

     

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


    Graphics


    Graphics


    Get the next $VANI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    SEC Filings

    View All

    Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    6/4/26 7:30:48 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    5/13/26 4:25:45 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Vivani Medical Inc.

    10-Q - Vivani Medical, Inc. (0001266806) (Filer)

    5/13/26 4:24:48 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,587,301 units at $1.26) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    5/19/26 8:31:16 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Williams Gregg

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    4/16/26 6:30:10 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    3/16/26 6:15:46 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

    ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Thursday, June 4, 2026Time: 11:05 a.m. - 11:35 a.m. Eastern Time Location: New York Marriott Marquis, 1535 Broadway Following the presentation, a replay will be available for 90 days on the Investors sec

    5/28/26 8:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

    Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. V

    5/13/26 4:05:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26

    3/26/26 4:16:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,587,301 units at $1.26) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    5/19/26 8:31:16 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    3/16/26 6:15:46 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Leadership Updates

    Live Leadership Updates

    View All

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Financials

    Live finance-specific insights

    View All

    Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

    Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent's new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke Vivani to sharpen focus on development of miniature, ultra long-acting GLP-1 implants for weight loss management and treatment of type 2 diabetes with once or twice-year

    9/17/25 8:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

    SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

    5/1/23 8:42:07 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Vivani Medical Inc.

    SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

    4/25/23 5:28:48 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care